Stocks · News reference
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG Therapeutics
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $65 to $72.